What is the 13F Pro Quality Score for SRPT?

13F Pro ranks Sarepta Therapeutics, Inc. (SRPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SRPT's current score at https://13fpro.ai/company/SRPT (free sign-up required for the full ranking).

Which hedge funds own the most SRPT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SRPT include BlackRock,, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SRPT as soon as new 13F filings post.

Where does 13F Pro source SRPT data?

All Sarepta Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sarepta Therapeutics, Inc. files with the SEC under CIK 873303. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SRPT in?

Sarepta Therapeutics, Inc. (SRPT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SRPT's revenue?

Per Sarepta Therapeutics, Inc.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Products, net ($659.2M, -41% YoY); Collaboration and other ($472.9M, +104% YoY); PMO Products ($459.1M, -2% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/SRPT.

What are SRPT's largest expenses?

Sarepta Therapeutics, Inc.'s latest 10-Q reports these as the largest expense items: Research and development ($245.2M, -75% YoY); Cost of sales (excluding amortization) ($258.2M, -11% YoY); Selling, general and administrative ($216.6M, -20% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (six months ended June 30, 2026).

How often is SRPT research updated on 13F Pro?

SRPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sarepta Therapeutics, Inc.(SRPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 873303 SRPT stock profile & AI dashboard →

13F Pro Quality Score

47.3/100

Rank #1,788 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

80.0/100

Profitability

20.4/100

Balance Sheet

24.4/100

Earnings Quality

59.5/100

Free Cash Flow

39.3/100

Institutional Flow

35.4/100

Revenue Scale

63.0/100

Dilution Risk

23.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SRPT Scores 47/100

exact factor attribution · 2026-09-11

SRPT's composite is driven by revenue growth and scale, held back by profitability and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.0 pts

80th pct

Scale

+1.9 pts

63th pct

Earnings quality

+0.9 pts

60th pct

Institutional flow

-0.7 pts

35th pct

Earnings growth

-0.9 pts

32th pct

Shareholder dilution

-1.3 pts

23th pct

Free cash flow

-1.6 pts

39th pct

Capital efficiency

-2.6 pts

24th pct

Profitability

-4.4 pts

20th pct

Latest change (2026-08-05): 42 → 70 · ↑ Profit margin 22→89; ↑ Free cash flow 11→73; despite ↓ Revenue growth 86→36

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in SRPT

Events flagged as statistical outliers against SRPT's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-05
SRPT quality score jumped 28 points (42→70) on a new filing
View source filing →

SRPT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Sarepta Therapeutics, Inc. (SRPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRPT at 47.3/100 on a 32-signal composite quality model, placing it at rank #1,788 of 2,962 stocks — the bottom half of the AI-ranked universe. SRPT scores in the top quartile across revenue growth (80.0). Areas of concern include profitability (20.4) and balance sheet strength (24.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Sarepta Therapeutics, Inc. reports quarterly revenue of $401.3M, net income of $-4.9M, an operating margin of 3.3%. Top institutional holders of SRPT by reported 13-F value include BlackRock, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. SRPT trades on the Nasdaq exchange and files with the SEC under CIK 873303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sarepta Therapeutics, Inc. directly from SEC EDGAR. Sarepta Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 30 and 70 since 2021, currently 47.3 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Sarepta Therapeutics, Inc.

Quirks, history, and lore behind SRPT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of roughly $1 billion, built almost entirely on a single rare disease franchise — blockbuster or bust.
3
The History
Founded in the early 1980s and spent decades as a scrappy biotech before pivoting hard into genetic medicine for devastating muscle-wasting diseases.
4
The Secret
Its signature strategy is exon skipping — a molecular trick that instructs the body to skip over a broken section of genetic code, like editing a typo out of a very important sentence.
5
The Lore
Its FDA approval pathway was one of the most contested in agency history, sparking fierce debate over accelerated approval for rare pediatric diseases — patients and scientists publicly clashed over the data.
6
The Giveaway
This company makes Elevidys, the first gene therapy approved for Duchenne muscular dystrophy — a disease that robs boys of their ability to walk, and whose families fought for this drug for decades.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SRPT's Business? Latest 10-Q Breakdown

AI-extracted from Sarepta Therapeutics, Inc.'s 10-Q filed 2026-08-05 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net income of $326.1M on total revenues of $1,132.1M, but ELEVIDYS sales collapsed 70% YoY to $200.1M due to safety suspensions and label restrictions, while PMO products declined 2% to $459.1M.

Biggest Revenue Drivers

Products, net$659.2M-41% YoY

Primarily driven by lower ELEVIDYS sales volume following safety events and label update restricting to ambulatory patients only.

Collaboration and other$472.9M+104% YoY

$365.0M from Roche declining option and first commercial dosing milestone; $85.5M contract manufacturing revenue from ELEVIDYS supply to Roche.

Biggest Revenue Drivers

Total revenue: $1,132.1M-17% YoY

Products, net$659.2M-41% YoY

Primarily driven by lower ELEVIDYS sales volume following safety events and label update restricting to ambulatory patients only.

Within Products, net

PMO Products$459.1M-2% YoY

U.S. and Rest of World PMO product sales remained relatively flat despite commercial challenges.

ELEVIDYS$200.1M-70% YoY

Sharp decline in U.S. sales from $656.8M to $200.1M reflecting suspension of non-ambulatory shipments and subsequent label restriction.

Collaboration and other$472.9M+104% YoY

$365.0M from Roche declining option and first commercial dosing milestone; $85.5M contract manufacturing revenue from ELEVIDYS supply to Roche.

Largest Expense Items

Research and development$245.2M-75% YoY

Reduced by $533.8M in up-front Arrowhead fees (prior year included $583.6M), lower SRP-9001 expenses, reduced clinical trials for paused LGMD programs, and headcount reductions from restructuring.

Cost of sales (excluding amortization)$258.2M-11% YoY

Decreased due to lower ELEVIDYS sales volume, partially offset by write-offs of batches not meeting quality specifications and increased Roche manufacturing costs.

Selling, general and administrative$216.6M-20% YoY

Reduced from lower commercialization spending for ELEVIDYS post-label restriction, reduced legal spending, and headcount reductions from restructuring.

Litigation contingency charge$39.0MNew

Recorded for potential resolution of certain patent litigations, with settlement subject to further negotiation and documentation.

Watch Items from the Filing

ELEVIDYS sales collapsed 70% YoY to $200.1M due to June 2025 suspension of non-ambulatory shipments, July 2025 full U.S. suspension, November 2025 boxed warning for acute liver injury/failure and removal of non-ambulatory population from label. Resumed ambulatory shipments July 31, 2025, but recovery uncertain.
ESSENCE trial for PMO Products (VYONDYS 53, AMONDYS 45) failed primary endpoint in November 2025; sNDAs filed April 2026, FDA accepted for filing June 2026. Risk of FDA label changes, revocation of accelerated approvals, or market withdrawal directives.
FDA placed clinical hold on SRP-9003 and other LGMD programs (SRP-9004, SRP-6004, SRP-9005) in July 2025 following patient death in SRP-9004 trial; SRP-9003 BLA submission delayed pending sirolimus immunosuppression study data. Company suspended LGMD development except SRP-9003 in July 2025 restructuring.
Litigation contingency charge of $39.0M recorded for potential resolution of patent litigations; settlement remains subject to negotiation. Nippon Shinyaku jury awarded Sarepta $115.2M in December 2024 for Viltepso infringement; Regenx vs. Sarepta patent litigation remanded by Federal Circuit February 2026 after reversal.
Customer concentration: as of June 30, 2026, four customers represent 34%, 24%, 21%, and 10% of accounts receivable, net ($376.8M). Product revenue concentration: two customers represented 35% and 22% of product revenues in Q2 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$401.3M

Net Income

Q2 2026

$-4.9M

Free Cash Flow

Q2 2026

$196.5M

Operating Margin

Q2 2026

3.3%

ROIC

Q2 2026

2.2%

D/E Ratio

Q2 2026

0.55

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+15.6% YoY

$2.20BFY 2025

FY22 $933.0MFY23 $1.24BFY24 $1.90BFY25 $2.20B

Net Income

-403.3% YoY

$-713.4MFY 2025

FY22 $-703.5MFY23 $-536.0MFY24 $235.2MFY25 $-713.4M

Operating Income

-420.9% YoY

$-699.8MFY 2025

FY22 $-536.2MFY23 $-267.8MFY24 $218.1MFY25 $-699.8M

EPS (Diluted)

-404.7% YoY

$-7.13FY 2025

FY22 $-8.03FY23 $-5.80FY24 $2.34FY25 $-7.13

Total Assets

-15.5% YoY

$3.35BFY 2025

FY22 $3.13BFY23 $3.26BFY24 $3.96BFY25 $3.35B

Total Debt

-27.1% YoY

$829.0MFY 2025

FY22 $1.54BFY23 $1.34BFY24 $1.14BFY25 $829.0M

Op. Cash Flow

+0.1% YoY

$-205.5MFY 2025

FY22 $-325.3MFY23 $-501.0MFY24 $-205.8MFY25 $-205.5M

Free Cash Flow

+10.3% YoY

$-307.5MFY 2025

FY22 $-356.2MFY23 $-577.1MFY24 $-342.7MFY25 $-307.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.20B +15.6%	$1.90B +53.0%	$1.24B +33.3%	$933.0M +32.9%	$701.9M +30.0%	$540.1M
Net Income	$-713.4M -403.3%	$235.2M +143.9%	$-536.0M +23.8%	$-703.5M -68.0%	$-418.8M +24.4%	$-554.1M
Operating Income	$-699.8M -420.9%	$218.1M +181.4%	$-267.8M +50.1%	$-536.2M -16.6%	$-459.7M +18.5%	$-564.2M
EPS (Diluted)	$-7.13 -404.7%	$2.34 +140.3%	$-5.80 +27.8%	$-8.03 -55.9%	$-5.15 +27.6%	$-7.11
Total Assets	$3.35B -15.5%	$3.96B +21.4%	$3.26B +4.4%	$3.13B -0.6%	$3.15B +5.5%	$2.98B
Total Debt	$829.0M -27.1%	$1.14B -15.4%	$1.34B -13.0%	$1.54B +174.0%	$563.7M	—
Operating Cash Flow	$-205.5M +0.1%	$-205.8M +58.9%	$-501.0M -54.0%	$-325.3M +26.6%	$-443.2M -512.4%	$107.5M
Free Cash Flow	$-307.5M +10.3%	$-342.7M +40.6%	$-577.1M -62.0%	$-356.2M +26.1%	$-481.7M -2006.5%	$25.3M

Get alerted when SRPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sarepta Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SRPT

BlackRock, Inc.
$341.3M18,994,958 sh
STATE STREET CORP
$160.2M8,916,090 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$150.5M8,377,470 sh
TWO SIGMA INVESTMENTS, LP
$82.6M4,598,735 sh
VANGUARD CAPITAL MANAGEMENT LLC
$82.5M4,591,755 sh
FIRST TRUST ADVISORS LP
$78.5M4,365,951 sh
AQR CAPITAL MANAGEMENT LLC
$76.9M4,325,689 sh
GEODE CAPITAL MANAGEMENT, LLC
$49.8M2,771,758 sh
HIGHBRIDGE CAPITAL MANAGEMENT LLC
$49.3M52,306,000 sh
Erste Asset Management GmbH
$45.5M2,568,945 sh

Fund	Value	Shares
BlackRock, Inc.	$341.3M	18,994,958
STATE STREET CORP	$160.2M	8,916,090
VANGUARD PORTFOLIO MANAGEMENT LLC	$150.5M	8,377,470
TWO SIGMA INVESTMENTS, LP	$82.6M	4,598,735
VANGUARD CAPITAL MANAGEMENT LLC	$82.5M	4,591,755
FIRST TRUST ADVISORS LP	$78.5M	4,365,951
AQR CAPITAL MANAGEMENT LLC	$76.9M	4,325,689
GEODE CAPITAL MANAGEMENT, LLC	$49.8M	2,771,758
HIGHBRIDGE CAPITAL MANAGEMENT LLC	$49.3M	52,306,000
Erste Asset Management GmbH	$45.5M	2,568,945

Companies Similar to SRPT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TDOC

Teladoc Health, Inc.

AI score

Similar quality profile · 15 shared holders

DeepCurrents Investment Group LLC Calamos Advisors LLC OAKTREE CAPITAL MANAGEMENT LP

NVAX

NOVAVAX INC

AI score

Similar quality profile · 17 shared holders

Virtus Investment Advisers, LLC MARTINGALE ASSET MANAGEMENT L P AXQ CAPITAL, LP

IONS

IONIS PHARMACEUTICALS INC

AI score

Similar quality profile · 18 shared holders

abrdn plc T. Rowe Price Investment Management, Inc.ADAR1 Capital Management, LLC

FTRE

Fortrea Holdings Inc.

AI score

Similar quality profile · 12 shared holders

SEGALL BRYANT & HAMILL, LLC Cinctive Capital Management LP MARTINGALE ASSET MANAGEMENT L P

MRNA

Moderna, Inc.

AI score

Similar quality profile · 10 shared holders

Casdin Capital, LLC Privium Fund Management B.V.Virtus Investment Advisers, LLC

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

AI score

Similar quality profile · 3 shared holders

abrdn plc Raiffeisen Bank International AG NORDEA INVESTMENT MANAGEMENT AB

EBS

Emergent BioSolutions Inc.

AI score

Similar quality profile · 8 shared holders

SEGALL BRYANT & HAMILL, LLC MARTINGALE ASSET MANAGEMENT L P GLOBEFLEX CAPITAL L P

ENOV

Enovis CORP

AI score

Similar quality profile · 14 shared holders

DeepCurrents Investment Group LLC OAKTREE CAPITAL MANAGEMENT LP Bridgewater Associates, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SRPT on your watchlist

Track score changes the day Sarepta Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SRPT a good stock to buy?

13F Pro's AI-powered analysis of Sarepta Therapeutics, Inc. (SRPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRPT are available on the SRPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SRPT is classified as a mid company.

Which hedge funds own SRPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sarepta Therapeutics, Inc.'s investment landscape.